Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer

Fig. 2

Validation of synergistic effect of EZH2/ATM inhibition. A Target inhibition of phosphorylated Kap1 (S824) after 72 h by increasing concentrations of AZD1390 (100 nM, 500 nM, 1 µM, 2 µM) treatment shown by a representative immunoblot in KB1P-G3 and KP-3.33 cells, GAPDH served as loading control. B Single agent dose–response curves and determination of IC50 value of AZD1390 in four mouse mammary tumor cell lines after 72 h treatment. C EZH2 inhibition specifically sensitizes BRCA1-deficient cells to ATM inhibition. The stacked bar graphs show the relative contribution to inhibition of cell viability by combined treatment with 7.5 µM GSK126/2 µM AZD1390 for 72 h. Statistical significance was tested by one-way ANOVA with Tukey multiple comparison test

Back to article page